Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 1,998 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares in the company, valued at $1,156,782.30. The trade was a 6.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mirum Pharmaceuticals Stock Down 1.6 %

MIRM opened at $41.32 on Friday. The company has a fifty day moving average of $42.95 and a two-hundred day moving average of $40.66. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -20.46 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $48.89. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.57) EPS. On average, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors have recently modified their holdings of MIRM. Mirae Asset Global Investments Co. Ltd. increased its stake in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after buying an additional 318 shares in the last quarter. Amalgamated Bank increased its position in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares in the last quarter. Arizona State Retirement System raised its stake in Mirum Pharmaceuticals by 10.6% in the 2nd quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock valued at $315,000 after purchasing an additional 883 shares during the last quarter. Quest Partners LLC lifted its holdings in Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in Mirum Pharmaceuticals by 17.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company’s stock worth $480,000 after purchasing an additional 2,050 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have weighed in on MIRM. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners upped their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.